Boeing secures $883 million Army contract for cargo support services
LOS ALTOS, Calif. - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a biotech company focusing on kidney disease treatments with a current market capitalization of $59 million, has shared insights from a new publication in the Journal of Nephrological Science. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 3.61, indicating solid short-term financial stability. The review, titled "Patient Perspectives: The Effects of Contemporary Phosphorus Management on Quality of Life," explores the difficulties kidney disease patients face with current phosphate management therapies.
The study highlights the importance of patient-centered approaches to improve clinical outcomes and patient satisfaction in chronic kidney disease (CKD), especially when patients often struggle with adherence to prescribed treatments. The review draws attention to the high non-adherence rates to phosphate binders, which are crucial in managing hyperphosphatemia in dialysis patients. Non-adherence rates range from 22% to 74%, with a mean rate of 51%, influenced by factors such as large pill size, high pill burden, and unpleasant side effects.
Unicycive's CEO, Dr. Shalabh Gupta, emphasizes the potential benefits of their product Oxylanthanum Carbonate (OLC), which is designed to address these issues with a smaller pill size and lower pill burden. The company is seeking FDA approval for OLC, which is currently under review with a target action date of June 28, 2025.
Hyperphosphatemia, if untreated, can lead to serious health complications, including cardiovascular diseases and increased mortality risk. The global market opportunity for treating this condition is estimated to exceed $2.28 billion, with North America accounting for over $1 billion.
Unicycive's OLC, a next-generation lanthanum-based phosphate binding agent, has over forty issued and granted patents globally. Its development is based on data from three clinical studies and multiple preclinical studies. If approved, OLC could offer significant improvements in adherence and clinical outcomes for CKD patients.
The company's pipeline also includes UNI-494, a new chemical entity in clinical development for acute kidney injury conditions, which has completed a Phase 1 trial. While the company is currently unprofitable, InvestingPro analysis shows that three analysts have revised their earnings upwards for the upcoming period, suggesting potential improvement in financial performance. InvestingPro subscribers have access to 8 additional key insights about UNCY's financial health and market position.
This article is based on a press release statement from Unicycive Therapeutics, Inc. Recent financial data from InvestingPro indicates the company holds more cash than debt on its balance sheet, though it's currently burning through cash at a notable rate. The stock has experienced significant volatility, with analyst price targets ranging from $2 to $9 per share.
In other recent news, Unicycive Therapeutics has been granted an extension until July 7, 2025, to meet Nasdaq's minimum bid price requirement. This comes after the company's failure to meet the initial deadline of January 6, 2025. Unicycive's continued listing on the Nasdaq Capital Market now depends on its ability to meet this requirement.
In the field of product development, Unicycive reported positive data from a Phase 1 study of oxylanthanum carbonate (OLC), a drug for patients with hyperphosphatemia in chronic kidney disease. The company is seeking FDA approval for OLC, with a target action date set for June 28, 2025. Additionally, Unicycive successfully completed its Phase 1 study for UNI-494, a drug aimed at treating acute kidney injury.
In terms of analyst ratings, H.C. Wainwright maintained a Buy rating for Unicycive following these developments. The company is also preparing to present new research on kidney disease therapies at the upcoming American Society of Nephrology Kidney Week. These are some of the recent developments in Unicycive Therapeutics' ongoing efforts in its clinical trials and regulatory endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.